← All trials
NCT06720233
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2002
- Primary completion
- Oct 18, 2024
- Completion date
- Oct 28, 2024
- First posted
- Dec 6, 2024
- Last posted
- Dec 6, 2024
- Enrollment
- 37
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
- Sun Yat-Sen UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.